ÆTERNA ZENTARIS

Pharmaceutical preparations used for the treatment of cancer; pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer; pharmaceutical preparations used for the treatment of urological diseases; pharmaceutical preparations used for the treatment of hormonal disorders; synthetic peptides-containing pharmaceutical preparations used for hormonal and tumors treatments; pharmaceutical preparations used for the treatment of endocrine diseases; pharmaceutical preparations used for the treatment of carcinoid tumors; pharmaceutical preparations used for the treatment of haematological diseases; pharmaceutical preparations used for the treatment of age-related diseases; pharmaceutical preparations used for the treatment of ophthalmological disorders; pharmaceutical preparations used for the treatment of reproductive system disorders; pharmaceutical preparations used for the treatment of endometriosis; pharmaceutical preparations used for the treatment of uterine myoma; pharmaceutical preparations used for the treatment of non-malignant tumors; pharmaceutical preparations used for the treatment of benign prostatic hyperplasia; pharmaceutical preparations used for the treatment of tropical diseases; pharmaceutical preparations used for the treatment of infectious disease; pharmaceutical preparations used for the treatment of leishmaniasis; pharmaceutical preparations used for the treatment of obesity; pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes; pharmaceutical preparations containing cytotoxic products, conjugated or not, for the treatment of cancer or infectious diseases; pharmaceutical preparations used as a tubulin inhibitor for the treatment of cancer; pharmaceutical preparations based on LHRH antagonists platform for the treatment of cancer, hormonal tumors, or hormonal disorders; pharmaceutical preparations based on bombesin antagonist platform for the treatment of cancer; pharmaceutical preparations based on inhibitors of the Akt pathway for the treatment of cancer or infectious diseases; pharmaceutical preparations based on angiogenesis inhibitors platform for the treatment of cancer; pharmaceutical preparations used to induce apoptosis; pharmaceutical preparations used to stimulate growth hormone secretagogue; vaccines for the treatment of tumors; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of respiratory diseases; pharmaceutical preparations for the treatment of gastrointestinal diseases; diagnostic agents, preparations and substances for medical purposes; pharmaceutical products, comprising growth hormone secretagogues, ghrelin receptor agonists, ghrelin receptor antagonists, ghrelin mimetics, growth hormone analogues, growth hormone fusion proteins, growth hormone releasing hormone analogues, auto immune modulating proteins, therapeutic antibodies, small molecule kinase inhibitors, phospholipids for the treatment of neurological disorders; pharmaceutical preparations for the treatment of nasopharyngeal disorders; antibiotics; antibacterial and fungicidal preparations; pharmaceutical preparations for the treatment of mental health; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of rheumatoid diseases; pharmaceutical preparations for contraceptives and women's health; analgesic pharmaceutical products, comprising small molecule kinase inhibitors, phospholipids, therapeutic antibodies, natural products; sedativa and pharmaceutical preparations for the treatment of psychiatric disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for palliative treatments; pharmaceutical preparations for the treatment of addictions; pharmaceutical formulations for the treatment of paediatric indications